US20080199494A1 - Vaccine - Google Patents
Vaccine Download PDFInfo
- Publication number
- US20080199494A1 US20080199494A1 US11/748,229 US74822907A US2008199494A1 US 20080199494 A1 US20080199494 A1 US 20080199494A1 US 74822907 A US74822907 A US 74822907A US 2008199494 A1 US2008199494 A1 US 2008199494A1
- Authority
- US
- United States
- Prior art keywords
- cpg
- nef
- hiv
- tat
- vaccine formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 32
- 238000009472 formulation Methods 0.000 claims abstract description 30
- 239000000427 antigen Substances 0.000 claims abstract description 21
- 102000036639 antigens Human genes 0.000 claims abstract description 21
- 108091007433 antigens Proteins 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 9
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 8
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims abstract 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- 230000004927 fusion Effects 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- 102000037865 fusion proteins Human genes 0.000 claims description 7
- 108020001507 fusion proteins Proteins 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 238000002649 immunization Methods 0.000 description 15
- 241000725303 Human immunodeficiency virus Species 0.000 description 14
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 13
- 241000282560 Macaca mulatta Species 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 101710149951 Protein Tat Proteins 0.000 description 8
- 229940037003 alum Drugs 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 229910001679 gibbsite Inorganic materials 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 101710192141 Protein Nef Proteins 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 description 3
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 159000000013 aluminium salts Chemical class 0.000 description 3
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001589 lymphoproliferative effect Effects 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229960004906 thiomersal Drugs 0.000 description 3
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 2
- 108091081548 Palindromic sequence Proteins 0.000 description 2
- 101710188053 Protein D Proteins 0.000 description 2
- 101710132893 Resolvase Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical group [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- YMVDTXSRLFAIKI-UHFFFAOYSA-N 7h-purine Chemical compound C1=NC=C2NC=NC2=N1.C1=NC=C2NC=NC2=N1 YMVDTXSRLFAIKI-UHFFFAOYSA-N 0.000 description 1
- 241000272478 Aquila Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- WTDPSUUWWKMZLE-UHFFFAOYSA-K P(=O)([O-])([O-])[O-].S(=O)(=O)(O)O.[Al+3] Chemical compound P(=O)([O-])([O-])[O-].S(=O)(=O)(O)O.[Al+3] WTDPSUUWWKMZLE-UHFFFAOYSA-K 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- YMXFJTUQQVLJEN-UHFFFAOYSA-N pyrimidine Chemical compound C1=CN=CN=C1.C1=CN=CN=C1 YMXFJTUQQVLJEN-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to new vaccine formulations and their use in the treatment or prophylaxis of HIV infections.
- the invention relates to the use of HIV antigen in conjunction with a CpG oligonucleotide.
- HIV is the primary cause of AIDS (acquired immune deficiency syndrome) and is regarded, as one of the worlds most pressing health issues. Although there has been extensive efforts to produce a successful vaccine, efforts to-date have failed to produce one. Accordingly, there remains a need for an improved HIV immunogenic composition.
- Immunomodulatory oligonucleotides contain unmethylated CpG dinucleotides (“CpG”) and are known (WO 96/02555, EP 468520).
- CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. Historically, it was observed that the DNA fraction of BCG could exert an anti-tumour effect.
- synthetic oligonucleotides derived from BCG gene sequences were shown to be capable of inducing immunostimulatory effects (both in vitro and in vivo). The authors of these studies concluded that certain palindromic sequences, including a central CG motif, carried this activity.
- CG motif has to be in a certain sequence context, and that such sequences are common in bacterial DNA but are rare in vertebrate DNA.
- Purine Purine CG pyrimidine pyrimidine and where the CG motif is not methylated In certain combinations of the six nucleotides a palindromic sequence is present. Several of these motifs, either as repeats of one motif or a combination of different motifs, can be present in the same oligonucleotide. The presence of one or more of these immunostimulatory sequence containing oligonucleotides can activate various immune subsets, including natural killer cells (which produce interferon ⁇ and have cytolytic activity) and macrophages (Wooldrige et al Vol 89 (no. 8), 1977). Although other unmethylated CpG containing sequences not having this consensus sequence have now been shown to be immunomodulatory.
- FIG. 1 HIV-1 gp120-specific antibody responses in immunized rhesus monkeys. Specific antibodies were evaluated in an ELISA. Individual values from multiple time points for each animal are shown in Table 1, and group averages are shown in Table 1 and as a graphic in FIG. 1 .
- FIG. 2 Gp120-specific lymphoproliferation in immunized rhesus monkeys 6 days post second immunization. PBMC were stimulated with gp120 antigen and lymphoproliferative responses were measured by 3 H-thymidine incorporation. Results are expressed in cpm and as SI.
- FIGS. 4 and 5 CD4 cell count and viral load data from Example 3 in which rhesus monkeys were immunised with Nef-Tat+gp120 formulated with CpG and challenged with pathogenic SHIV.
- the present invention provides an improved vaccine formulation comprising a CpG oligonucleotide and an HIV antigen selected from the group HIV gp160, HIV gp120; an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or derivative thereof, or an HIV Tat protein or derivative thereof linked to either (i) a fusion protein or (ii) an HIV Nef protein or derivative thereof, or an HIV Nef protein or derivative thereof linked to an HIV Tat protein or derivative thereof and a fusion partner.
- fusion partner is meant any protein sequence that is not Tat or Nef.
- the fusion partner is protein D or its lipidated derivative Lipoprotein D, from Haemophilus influenzae B.
- the N-terminal third i.e. approximately the first 100-130 amino acids are utilised. This is represented herein as Lipo D 1/3.
- the Nef protein or derivative thereof may be linked to the Tat protein or derivative thereof.
- Such Nef-Tat fusions may optionally also be linked to a fusion partner, such as protein D.
- the fusion partner is normally linked to the N-terminus of the Nef or Tat protein.
- Derivatives encompassed within the present invention include molecules with a C terminal Histidine tail, which preferably comprises between 5-10 Histidine residues. Generally, a histidine tail containing n residues is represented herein as His (n). The presence of a histidine (or ‘His’) tail aids purification. More specifically, the invention provides vaccines comprising proteins with the following structure:
- the proteins are expressed with a Histidine tail comprising between 5 to 10 and preferably six Histidine residues. These are advantageous in aiding purification.
- yeast Saccharomyces cerevisiae
- Nef Macreadie I G et al 1993, Yeast 9 (6) 565-573
- Tat Braindock M et al, 1989, Cell 58 (2) 269-79
- the present invention also provides vaccines comprising Nef and/or Tat separately.
- the DNA and amino acid sequences of representative Nef-His, Tat-His and of Nef-Tat-His fusion proteins as set forth in WO99/16884.
- Particularly preferred vaccines according to the invention comprise an HIV fusion protein such as Nef-Tat and optionally an additional HIV protein.
- Particularly preferred in a vaccine formulation according to the invention is a combination of an HIV fusion protein plus gp120, more particularly Nef-Tat with gp120.
- Derivatives encompassed within the present invention also include mutated proteins.
- the term ‘mutated’ is used herein to mean a molecule which has undergone deletion, addition or substitution of one or more amino acids using well known techniques for site directed mutagensis or any other conventional method.
- Vaccine preparation is generally described in Vaccine Design—The subunit and adjuvant approach (Ed. Powell and Newman) Pharmaceutical Biotechnology Vol. 6 Plenum Press 1995. Encapsulation within liposomes is described by Fullerton, U.S. Pat. No. 4,235,877.
- the preferred oligonucleotides preferably contain two or more CpG motifs separated by six or more nucleotides.
- the oligonucleotides of the present invention are typically deoxynucleotides.
- the internucleotide in the oligonucleotide is phosphorodithioate, or more preferably a phosphorodithioate bond, although phosphodiester and other internucleotide bonds are within the scope of the invention including oligonucleotides with mixed internucleotide linkages.
- Preferred oligonucleotides have the following sequences:
- Oligo 5′-SEQUENCE-3′ CpG Thio WD1001 TCC ATG ACG TTC CTG ACG TT + + (SEQ ID NO:1) WD1002 TCT CCC AGC GTG CGC CAT + + (SEQ ID NO:2) WD1003 ACC GAT AAC GTT GCC GGT GAC G + ⁇ (SEQ ID NO:3) WD1004 G*G*G GTC AAC GTT GAG* G*G*G* + Mix G*G (SEQ ID NO:4) WD1005 TCC ATG AGC TTC CTG AGC TT ⁇ + (SEQ ID NO:5) WD1006 TCC ATG ACG TTC CTG ACG TT + ⁇ (SEQ ID NO:6) WD1007 ACC GAT GAC GTC GCC GGT GAC + + GGC ACC ACG TCG TTT TGT + + CGT TTT GTC GTT (SEQ ID NO:7) *alternatively referred to as
- a+ in the Thio column indicates the presence of a thioate modification.
- ‘Mix’ indicates a mixture of thioate modification and sequence without thioate modification (the asterisks indicate the linkages with a thioate modification).
- a ⁇ in the Thio column indicates absence of a thioate modification.
- a + in the CpG column indicates a the presence of a CpG motif and a ⁇ in the CpG column indicates absence of a CpG motif.
- WD1005 contains a GpC rather than a CpG motif, thus it is marked with a ⁇ in the CpG column of the table.
- WD1007 contains a palindromic motif (GACGTC) as well as other non-palindromic CpG sequences. This is also within the scope of a CpG oligonucleotide as the term is used in the present application.
- the CpG oligonucleotides utilised in the present invention may be synthesized by any method known in the art (eg EP 0 468 520). Conveniently, such oligonucleotides may be synthesized utilising an automated synthesizer. Methods for producing phosphorothioate oligonucleotides or phosphorodithioate are described in U.S. Pat. No. 5,666,153, U.S. Pat. No. 5,278,302 and WO 95/26204.
- each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccinees. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 ⁇ g of protein, preferably 2-500 ⁇ g, most preferably 5-250 ⁇ g. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisations adequately spaced.
- a method of treating a human in need thereof either with a vaccine composition comprising an HIV antigen and a CpG oligonucleotide (as hereinabove defined) or with the CpG oligonucleotide followed after a suitable time by the HIV antigen.
- kits comprising effective amounts of a CpG oligonucleotide-containing formulation for use as a priming formulation for pre-administration to human patients and an HIV antigen for injection at some suitable time later, as described hereinabove.
- Preferred CpG oligonucleotides are those indicated in the table hereinabove.
- the CpG will be present in the range 10 ⁇ g per dose to 2000 ⁇ g, preferably 50-1000 ⁇ g, such as about 50 or about 500 or about 1000 ⁇ g per dose.
- the vaccine used in the present invention may comprise a carrier such as an aluminium salt, eg aluminium hydroxide (Al(OH) 3 ), aluminium phosphate or aluminium phosphate sulfate (alum), or a non-toxic oil in water emulsion or a mixture thereof.
- a carrier such as an aluminium salt, eg aluminium hydroxide (Al(OH) 3 ), aluminium phosphate or aluminium phosphate sulfate (alum), or a non-toxic oil in water emulsion or a mixture thereof.
- an aluminium salt preferably aluminium hydroxide
- it is generally present in the range of 50 to 100 ⁇ g, preferably 100 to 500 ⁇ g per dose.
- Non-toxic oil in water emulsions preferably contain a non-toxic oil, eg squalene and an emulsifier such as (polysorbitan monoleate) Tween 80, in an aqueous carrier such as phosphate buffered saline.
- a non-toxic oil eg squalene and an emulsifier such as (polysorbitan monoleate) Tween 80
- an aqueous carrier such as phosphate buffered saline.
- the vaccine used in the present invention may comprise an additional adjuvant, preferably a saponin adjuvant such as QS21 as described for example in WO 9517210, optionally in the presence of a sterol, such as cholesterol as described for example in PCT/EP96/01464.
- the vaccine of the invention may also comprise monophosphoryl lipid A and derivatives thereof known in the art.
- a preferred derivative is 3 de-O-acylated monophosphoryl lipid A, described in British Patent No. GB 2 220 211.
- vaccine formulations of the present invention may additionally comprise other pharmaceutical excipients or immunostimulants.
- the vaccine formulation additionally comprises an aluminium salt, preferably aluminium hydroxide.
- a saponin adjuvant may also be included such as QS21 (Aquila).
- Formulations were prepared one day before each injection. All incubations were carried out at room temperature with agitation.
- Gp120 (50 ⁇ g) was adsorbed on 500 ⁇ g of Al(OH) 3 for 1 hour.
- the formulation was buffered with a 10-fold concentrated PO 4 /NaCl pH 6.8 solution before addition of 500 ⁇ g of WD001. After 15 min, 50 ⁇ g/ml of thiomersal was added as preservative.
- Gp120 (50 ⁇ g) was diluted in PO 4 /NaCl buffer pH 6.8 before addition of 500 ⁇ g of CpG WD001. After 15 min, 50 ⁇ g/ml of thiomersal was added as preservative.
- rhesus monkeys ( Macaca mulatta ) per group were immunized twice intramuscularly with 500 ⁇ l of vaccine at a four-week-interval.
- Sera and peripheral blood mononuclear cells were taken at several occasions.
- Gp120-specific antibodies in sera of immunized monkeys were determined in an ELISA as described in Mooij et al., (Mooij, P., Van der Kolk, M., Bogers, M. J. M., et al. (1998).
- a clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection. AIDS 12:F15-F22).
- ELISA plates were coated with 1 ⁇ g/ml gp120, saturated with BSA and subjected to incubation with rhesus monkey sera followed by ⁇ -human biotinylated antibody. Finally, HRP-streptavidin was added and quantified in a color reaction using OPD as substrate.
- IFN- ⁇ -secreting cells were investigated in all monkeys before immunization and 6 days after the second dose. IFN- ⁇ -secreting cells could not be evaluated from pre-immunization samples due to technical difficulties. However, such cells were detectable after secondary immunization ( FIG. 3 ). All animals in both groups exhibited an antigen-specific response.
- Immunization with HIV-1 gp120 in combination with CpG or CpG/alum induces immune responses in non-human primates. These responses include gp120-specific antibodies, lymphoproliferation and IFN- ⁇ -secreting cells.
- the antigens prepared according to WO99/16884 were dialysed against NaCl 150 mM to eliminate the PO 4 ions that inhibit the adsorption of gp120 on Al(OH) 3 .
- the antigens were incubated with the CpG before adsorption on Al(OH) 3 to favour a potential interaction between the His tail of the Nef-Tat and Nef antigens and the oligonucleotide.
- the formulation was centrifuged and the supernatant was analsyed by SDS-PAGE (Novex 4-20%, reducing conditions) to check the adsorption of HIV Nef-Tat.
- the gel was stained with silver. Gel analysis of the formulation revealed that most of the Nef or Nef-Tat protein was adsorbed onto alum.
- a vaccine formulation was prepared in accordance with the invention comprising a Nef-Tat fusion protein and gp120 together with an oligonucleotide containing unmethylated CpG dinucleotide motifs and aluminium hydroxide as carrier.
- CpG dry powder is dissolved in H 2 O to give a solution of 5 mg/ml CpG.
- the 3 antigens were dialyzed against NaCl 150 mM to eliminate the phosphate ions that inhibit the adsorption of gp120 on aluminium hydroxide.
- the antigens diluted in H 2 O (100 ⁇ g gp120, 20 ⁇ g NefTat and 20 ⁇ g SIV Nef) were incubated with the CpG solution (500 ⁇ g CpG) for 30 min before adsorption on Al(OH) 3 to favor a potential interaction between the His tail of NefTat and Nef antigens and the oligonucleotide (stronger immunostimulatory effect of CpG described when bound to the antigen compared to free CpG). Then Al(OH) 3 (500 ⁇ g), 10 fold concentrated NaCl and 1 ⁇ g/ml thiomersal as preservative were consecutively added at 5 min intervals.
- CD4-positive cells declined after challenge. All four animals exhibited a slight decrease in CD4-positive cells and recovered to baseline levels over time ( FIG. 4 ). In contrast, three out of four animals in an adjuvant alone control group exhibited a drop of CD4-positive cells below 5% and never recovered.
- Virus load data are almost the inverse of CD4 data ( FIG. 5 ). Virus load decreased in the animals that had received NefTat+gp120 formulated with CpG containing oligonucleotide, but remained high in three out of four control animals which received only an adjuvant.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Paper (AREA)
- Peptides Or Proteins (AREA)
Abstract
A vaccine formulation for the prevention or amelioration of HIV infection in humans is provided. The vaccine comprises an HIV antigen, especially a protein which comprises Nef and/or Tat of HIV, and an immunostimulatory CpG oligonucleotide. Methods for making the vaccine formulation of the invention are described. Patients may also be treated by pre-administration of the CpG oligonucleotide prior to administration of the HIV antigen.
Description
- This application is a continuation of U.S. Ser. No. 10/018,695, filed on 26 Jun. 2002, which is a §371 of International Application No. PCT/EP00/05998, filed 28 Jun. 2000, which claims benefit from the following GB Provisional Applications: No. 9915205.0, filed Jun. 29, 1999, and No. 0002200.4, filed Jan. 31, 2000.
- The present invention relates to new vaccine formulations and their use in the treatment or prophylaxis of HIV infections. In particular the invention relates to the use of HIV antigen in conjunction with a CpG oligonucleotide.
- HIV is the primary cause of AIDS (acquired immune deficiency syndrome) and is regarded, as one of the worlds most pressing health issues. Although there has been extensive efforts to produce a successful vaccine, efforts to-date have failed to produce one. Accordingly, there remains a need for an improved HIV immunogenic composition.
- International Patent Application No. 92/06113 relates to vaccine formulation comprising the envelope protein gp160 and its naturally occurring derivative gp120 adjuvanted 3 deacylated monophosphoryl lipid A and a suitable carrier such as aluminium hydroxide.
- International Patent Application No. 99/16884 describes vaccine formulations based on non-envelope HIV proteins, Nef and Tat, particularly fusions of the Nef protein with Tat, and fusions of the Nef protein with Tat or an immunological fusion partner.
- Immunomodulatory oligonucleotides contain unmethylated CpG dinucleotides (“CpG”) and are known (WO 96/02555, EP 468520). CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. Historically, it was observed that the DNA fraction of BCG could exert an anti-tumour effect. In further studies, synthetic oligonucleotides derived from BCG gene sequences were shown to be capable of inducing immunostimulatory effects (both in vitro and in vivo). The authors of these studies concluded that certain palindromic sequences, including a central CG motif, carried this activity. The central role of the CG motif in immunostimulation was later elucidated in a publication by Krieg, Nature 374, p546 1995. Detailed analysis has shown that the CG motif has to be in a certain sequence context, and that such sequences are common in bacterial DNA but are rare in vertebrate DNA.
- It is currently believed that this evolutionary difference allows the vertebrate immune system to detect the presence of bacterial DNA (as occurring during an infection) leading consequently to the stimulation of the immune system. The immunostimulatory sequence as defined by Krieg is:
- Purine Purine CG pyrimidine pyrimidine and where the CG motif is not methylated. In certain combinations of the six nucleotides a palindromic sequence is present. Several of these motifs, either as repeats of one motif or a combination of different motifs, can be present in the same oligonucleotide. The presence of one or more of these immunostimulatory sequence containing oligonucleotides can activate various immune subsets, including natural killer cells (which produce interferon γ and have cytolytic activity) and macrophages (Wooldrige et al Vol 89 (no. 8), 1977). Although other unmethylated CpG containing sequences not having this consensus sequence have now been shown to be immunomodulatory.
-
FIG. 1 : HIV-1 gp120-specific antibody responses in immunized rhesus monkeys. Specific antibodies were evaluated in an ELISA. Individual values from multiple time points for each animal are shown in Table 1, and group averages are shown in Table 1 and as a graphic inFIG. 1 . -
FIG. 2 : Gp120-specific lymphoproliferation in immunized rhesus monkeys 6 days post second immunization. PBMC were stimulated with gp120 antigen and lymphoproliferative responses were measured by 3H-thymidine incorporation. Results are expressed in cpm and as SI. -
FIG. 3 : Gp120-specific IFN-γ-secreting cells from immunized rhesus monkeys. IFN-γ-secreting cells were visualized by the ELIspot method. Cytokine-secreting cells resulting in a colored spot were enumerated by microscopic examination and results are expressed semi-quantitatively (−=0-5, +=5-15, ++=15-35, +++=35-50, ++++=>50). -
FIGS. 4 and 5 : CD4 cell count and viral load data from Example 3 in which rhesus monkeys were immunised with Nef-Tat+gp120 formulated with CpG and challenged with pathogenic SHIV. - The present invention provides an improved vaccine formulation comprising a CpG oligonucleotide and an HIV antigen selected from the group HIV gp160, HIV gp120; an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or derivative thereof, or an HIV Tat protein or derivative thereof linked to either (i) a fusion protein or (ii) an HIV Nef protein or derivative thereof, or an HIV Nef protein or derivative thereof linked to an HIV Tat protein or derivative thereof and a fusion partner.
- By ‘fusion partner’ is meant any protein sequence that is not Tat or Nef. Preferably the fusion partner is protein D or its lipidated derivative Lipoprotein D, from Haemophilus influenzae B. In particular, it is preferred that the N-terminal third, i.e. approximately the first 100-130 amino acids are utilised. This is represented herein as Lipo D 1/3. In a preferred embodiment of the invention the Nef protein or derivative thereof may be linked to the Tat protein or derivative thereof. Such Nef-Tat fusions may optionally also be linked to a fusion partner, such as protein D.
- If present, the fusion partner is normally linked to the N-terminus of the Nef or Tat protein.
- Derivatives encompassed within the present invention include molecules with a C terminal Histidine tail, which preferably comprises between 5-10 Histidine residues. Generally, a histidine tail containing n residues is represented herein as His (n). The presence of a histidine (or ‘His’) tail aids purification. More specifically, the invention provides vaccines comprising proteins with the following structure:
-
Lipo D ⅓ Nef His (6) Lipo D ⅓ Nef-Tat His (6) Prot D ⅓ Nef His (6) Prot D ⅓ Nef-Tat His (6) Nef-Tat His (6) - In a preferred embodiment the proteins are expressed with a Histidine tail comprising between 5 to 10 and preferably six Histidine residues. These are advantageous in aiding purification. Separate expression, in yeast (Saccharomyces cerevisiae), of Nef (Macreadie I G et al 1993, Yeast 9 (6) 565-573) and Tat (Braddock M et al, 1989, Cell 58 (2) 269-79) has already been reported. Nef protein only is myristilated. The present invention also provides vaccines comprising Nef and/or Tat separately. The DNA and amino acid sequences of representative Nef-His, Tat-His and of Nef-Tat-His fusion proteins as set forth in WO99/16884.
- Particularly preferred vaccines according to the invention comprise an HIV fusion protein such as Nef-Tat and optionally an additional HIV protein. Particularly preferred in a vaccine formulation according to the invention is a combination of an HIV fusion protein plus gp120, more particularly Nef-Tat with gp120.
- Derivatives encompassed within the present invention also include mutated proteins. The term ‘mutated’ is used herein to mean a molecule which has undergone deletion, addition or substitution of one or more amino acids using well known techniques for site directed mutagensis or any other conventional method.
- Vaccine preparation is generally described in Vaccine Design—The subunit and adjuvant approach (Ed. Powell and Newman) Pharmaceutical Biotechnology Vol. 6 Plenum Press 1995. Encapsulation within liposomes is described by Fullerton, U.S. Pat. No. 4,235,877.
- The preferred oligonucleotides preferably contain two or more CpG motifs separated by six or more nucleotides. The oligonucleotides of the present invention are typically deoxynucleotides. In a preferred embodiment the internucleotide in the oligonucleotide is phosphorodithioate, or more preferably a phosphorodithioate bond, although phosphodiester and other internucleotide bonds are within the scope of the invention including oligonucleotides with mixed internucleotide linkages.
- Preferred oligonucleotides have the following sequences:
-
Oligo (internal designation*) 5′-SEQUENCE-3′ CpG Thio WD1001 TCC ATG ACG TTC CTG ACG TT + + (SEQ ID NO:1) WD1002 TCT CCC AGC GTG CGC CAT + + (SEQ ID NO:2) WD1003 ACC GAT AAC GTT GCC GGT GAC G + − (SEQ ID NO:3) WD1004 G*G*G GTC AAC GTT GAG* G*G*G* + Mix G*G (SEQ ID NO:4) WD1005 TCC ATG AGC TTC CTG AGC TT − + (SEQ ID NO:5) WD1006 TCC ATG ACG TTC CTG ACG TT + − (SEQ ID NO:6) WD1007 ACC GAT GAC GTC GCC GGT GAC + + GGC ACC ACG TCG TCG TTT TGT + + CGT TTT GTC GTT (SEQ ID NO:7) *alternatively referred to as WD001-WD007 - In the above table a+ in the Thio column indicates the presence of a thioate modification. ‘Mix’ indicates a mixture of thioate modification and sequence without thioate modification (the asterisks indicate the linkages with a thioate modification). A − in the Thio column indicates absence of a thioate modification. A + in the CpG column indicates a the presence of a CpG motif and a − in the CpG column indicates absence of a CpG motif. For example WD1005 contains a GpC rather than a CpG motif, thus it is marked with a − in the CpG column of the table. WD1007 contains a palindromic motif (GACGTC) as well as other non-palindromic CpG sequences. This is also within the scope of a CpG oligonucleotide as the term is used in the present application.
- The CpG oligonucleotides utilised in the present invention may be synthesized by any method known in the art (eg
EP 0 468 520). Conveniently, such oligonucleotides may be synthesized utilising an automated synthesizer. Methods for producing phosphorothioate oligonucleotides or phosphorodithioate are described in U.S. Pat. No. 5,666,153, U.S. Pat. No. 5,278,302 and WO 95/26204. - The amount of protein in each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccinees. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 μg of protein, preferably 2-500 μg, most preferably 5-250 μg. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisations adequately spaced.
- It is also possible to pre-administer the CpG oligonucleotide shortly prior to vaccination with the HIV antigen, for example 1 day before.
- Accordingly, according to another aspect of the invention there is provided a method of treating a human in need thereof either with a vaccine composition comprising an HIV antigen and a CpG oligonucleotide (as hereinabove defined) or with the CpG oligonucleotide followed after a suitable time by the HIV antigen.
- There is also provided a kit comprising effective amounts of a CpG oligonucleotide-containing formulation for use as a priming formulation for pre-administration to human patients and an HIV antigen for injection at some suitable time later, as described hereinabove.
- Preferred CpG oligonucleotides are those indicated in the table hereinabove.
- Suitably the CpG will be present in the
range 10 μg per dose to 2000 μg, preferably 50-1000 μg, such as about 50 or about 500 or about 1000 μg per dose. - Suitably the vaccine used in the present invention may comprise a carrier such as an aluminium salt, eg aluminium hydroxide (Al(OH)3), aluminium phosphate or aluminium phosphate sulfate (alum), or a non-toxic oil in water emulsion or a mixture thereof.
- If an aluminium salt (preferably aluminium hydroxide) is used as a carrier it is generally present in the range of 50 to 100 μg, preferably 100 to 500 μg per dose.
- Non-toxic oil in water emulsions preferably contain a non-toxic oil, eg squalene and an emulsifier such as (polysorbitan monoleate) Tween 80, in an aqueous carrier such as phosphate buffered saline.
- If desired the vaccine used in the present invention may comprise an additional adjuvant, preferably a saponin adjuvant such as QS21 as described for example in WO 9517210, optionally in the presence of a sterol, such as cholesterol as described for example in PCT/EP96/01464. The vaccine of the invention may also comprise monophosphoryl lipid A and derivatives thereof known in the art. A preferred derivative is 3 de-O-acylated monophosphoryl lipid A, described in British Patent No.
GB 2 220 211. - Accordingly vaccine formulations of the present invention may additionally comprise other pharmaceutical excipients or immunostimulants. In a preferred embodiment the vaccine formulation additionally comprises an aluminium salt, preferably aluminium hydroxide. In a further embodiment a saponin adjuvant may also be included such as QS21 (Aquila).
- The present invention will now be described with reference to the following examples:
- An immunogenicity study was conducted to evaluate the adjuvant effect of CpG in non-human primates. Groups of five monkeys were immunized twice with HIV-1W6.1D gp120 in combination with CpG or CpG/alum. After the second immunization the immune response of the animals was assessed. Antibodies to gp120 and lymphoproliferative as well as cytokine responses were evaluated.
-
-
Group antigen Adjuvant 1 HIV-1w6.1 gp120 CpG/ alum 2 HIV-1w6.1 gp120 CpG -
-
CONCEN- BATCH TRATION COMPONENT BRAND NUMBER (MG/ML) BUFFER Gp120* 47/025 0.456 PBS Al(OH)3 Superfos 96A0089 10.380 H2O CpG WD001 5 H2O *gp120 of HIV-1 clone W6.1D (Groenink, M., Fouchier, R. A., De Goede, R. E., et al. (1991). Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J. Virol. 65: 1968-1975.) - Formulations were prepared one day before each injection. All incubations were carried out at room temperature with agitation.
- CpG/Alum Group 1 (500 μl/Dose)
- Gp120 (50 μg) was adsorbed on 500 μg of Al(OH)3 for 1 hour. The formulation was buffered with a 10-fold concentrated PO4/NaCl pH 6.8 solution before addition of 500 μg of WD001. After 15 min, 50 μg/ml of thiomersal was added as preservative.
- CpG Group 2 (500 μl/Dose)
- Gp120 (50 μg) was diluted in PO4/NaCl buffer pH 6.8 before addition of 500 μg of CpG WD001. After 15 min, 50 μg/ml of thiomersal was added as preservative.
- Five rhesus monkeys (Macaca mulatta) per group were immunized twice intramuscularly with 500 μl of vaccine at a four-week-interval. Sera and peripheral blood mononuclear cells (PBMC) were taken at several occasions.
- Gp120-specific antibodies in sera of immunized monkeys were determined in an ELISA as described in Mooij et al., (Mooij, P., Van der Kolk, M., Bogers, M. J. M., et al. (1998). A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection. AIDS 12:F15-F22). Briefly, ELISA plates were coated with 1 μg/ml gp120, saturated with BSA and subjected to incubation with rhesus monkey sera followed by α-human biotinylated antibody. Finally, HRP-streptavidin was added and quantified in a color reaction using OPD as substrate.
- Lymphoproliferation was assessed by using density gradient-purified PBMC from immunized rhesus monkeys. Cells were seeded in quadruplicates at 1×105 in 100 μl RPMI/5% FCS per well in round bottom 96 well plates. Then another 100 μl of medium alone or containing soluble gp120 (10 μg/ml) were added and parallel cultures were incubated for 48 hrs. Thereafter, 100 μl culture supernatant were replaced by fresh medium containing 1 μCi [3H]-thymidine. After 16 hrs cells were harvested onto filter plates and incorporated radioactivity was determined in a β-counter. Results are expressed in cpm and in stimulation indices (SI,=cpm antigen-containing cultures/cpm medium alone cultures), SI greater than 3 are considered as a positive response.
- Flat bottom 96 well plates were prepared by coating an IFN-γ-specific capture antibody in 50 μl PBS for 4 hrs at 37° C. The plates were washed three times and PBMC were seeded similar to lymphoproliferation assays. After 48 hrs of culture the plates were washed thrice with PBS/0.05
% Tween - Analysis of gp120-specific antibodies in sera of the monkeys revealed that all animals in the two groups had acquired specific immune responses (Table 1 and
FIG. 1 ). Some low responses were detectable in two animals already after one immunization. After the second immunization all animals exhibited high titers of gp120-specific antibodies. -
TABLE 1 d-12 average 14 d post 1average 7 d post II average 28 d post II average Group 1 N5V <100 <100 188 <50 6445 5530 2014 2504 1055 <100 50 4699 1484 R441 <100 50 2942 827 BXJ <100 50 5808 4013 CPJ <100 50 7758 4184 Group 2NJ5 <100 <100 50 <50 734 3358 729 963 X006 <100 50 4182 1171 1041 <100 50 2834 400 R361 <100 258 5227 1821 BBE <100 50 3811 693 - Induction of specific lymphoproliferation by immunization with gp120 in combination with CpG or CpG/alum was evaluated before immunization and 6 days post secondary immunization. All 10 animals did not exhibit any specific lymphoproliferation (SI>3) at the study start (data not shown). In contrast, all animals in
group 1 possessed strong lymphoproliferative responses 6 days post boost immunization (FIG. 2 ). Similarly, all except one animal ingroup 2 showed specific lymphoproliferation. - The presence of gp120-specific IFN-γ-secreting cells was investigated in all monkeys before immunization and 6 days after the second dose. IFN-γ-secreting cells could not be evaluated from pre-immunization samples due to technical difficulties. However, such cells were detectable after secondary immunization (
FIG. 3 ). All animals in both groups exhibited an antigen-specific response. - Immunization with HIV-1 gp120 in combination with CpG or CpG/alum induces immune responses in non-human primates. These responses include gp120-specific antibodies, lymphoproliferation and IFN-γ-secreting cells.
- The antigens prepared according to WO99/16884 were dialysed against NaCl 150 mM to eliminate the PO4 ions that inhibit the adsorption of gp120 on Al(OH)3.
- The formulation sequence is as described below:
- The antigens were incubated with the CpG before adsorption on Al(OH)3 to favour a potential interaction between the His tail of the Nef-Tat and Nef antigens and the oligonucleotide.
- The formulation was centrifuged and the supernatant was analsyed by SDS-PAGE (Novex 4-20%, reducing conditions) to check the adsorption of HIV Nef-Tat. The gel was stained with silver. Gel analysis of the formulation revealed that most of the Nef or Nef-Tat protein was adsorbed onto alum.
- A vaccine formulation was prepared in accordance with the invention comprising a Nef-Tat fusion protein and gp120 together with an oligonucleotide containing unmethylated CpG dinucleotide motifs and aluminium hydroxide as carrier.
- Preparation of CpG oligonucleotide solution: CpG dry powder is dissolved in H2O to give a solution of 5 mg/ml CpG.
- The 3 antigens were dialyzed against NaCl 150 mM to eliminate the phosphate ions that inhibit the adsorption of gp120 on aluminium hydroxide.
- The antigens diluted in H2O (100 μg gp120, 20 μg NefTat and 20 μg SIV Nef) were incubated with the CpG solution (500 μg CpG) for 30 min before adsorption on Al(OH)3 to favor a potential interaction between the His tail of NefTat and Nef antigens and the oligonucleotide (stronger immunostimulatory effect of CpG described when bound to the antigen compared to free CpG). Then Al(OH)3 (500 μg), 10 fold concentrated NaCl and 1 μg/ml thiomersal as preservative were consecutively added at 5 min intervals.
- All incubations were carried out at room temperature with agitation.
- Four rhesus monkeys were immunized intramuscularly at 0, 1 and 3 months with the vaccine composition.
- One month after the last immunization all animals were challenged with a pathogenic SHIV (strain 89.6p). From the week of challenge (wk16) blood samples were taken periodically at the indicated time points to determine the % of CD4-positive cells among peripheral blood mononuclear cells by FACS analysis (
FIG. 4 ) and the concentration of RNA viral genomes in the plasma by bDNA assay (FIG. 5 ). - All animals became infected after challenge with SHIV89.6p.
- CD4-positive cells declined after challenge. All four animals exhibited a slight decrease in CD4-positive cells and recovered to baseline levels over time (
FIG. 4 ). In contrast, three out of four animals in an adjuvant alone control group exhibited a drop of CD4-positive cells below 5% and never recovered. - Virus load data are almost the inverse of CD4 data (
FIG. 5 ). Virus load decreased in the animals that had received NefTat+gp120 formulated with CpG containing oligonucleotide, but remained high in three out of four control animals which received only an adjuvant. - At
week 44 2/4 animals in a control group treated with only an adjuvant had to be euthanized due to AIDS-like symptoms. - The combination of gp120 and NefTat (in the presence of SIV Nef) with CpG adjuvant prevents the loss of CD4-positive cells and reduces the virus load in animals infected with pathogenic SHIV89.6p.
Claims (8)
1. A vaccine formulation comprising a combination of an HIV antigen selected from the group consisting of gp120, Nef, Tat, Nef-Tat fusions and 10 μg per dose to 2000 μg per dose an immunostimulatory CpG oligonucleotide.
2. The vaccine formulation of claim 1 , wherein the HIV fusion protein is a Nef-Tat fusion protein.
3. The vaccine formulation of claim 1 , additionally comprising a saponin adjuvant.
4. The vaccine formulation of claim 1 , wherein the oligonucleotide comprises two CpG dinucleotides.
5. The vaccine formulation of claim 1 , wherein the CpG oligonucleotide is between 15-45 nucleotides in length.
6. The vaccine formulation of claim 1 , wherein the oligonucleotide is selected from the group: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:7.
7. The vaccine formulation of claim 1 , wherein said antigen and CpG oligonucleotide are formulated as an oil in water emulsion.
8. A method for the prevention or amelioration of HIV infection in a patient comprising administering to the patient an effective amount of the vaccine formulation of claim 1 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/748,229 US20080199494A1 (en) | 1999-06-29 | 2007-05-14 | Vaccine |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9915205.0 | 1999-06-29 | ||
GBGB9915205.0A GB9915205D0 (en) | 1999-06-29 | 1999-06-29 | Vaccine |
GB0002200.4 | 2000-01-31 | ||
GB0002200A GB0002200D0 (en) | 2000-01-31 | 2000-01-31 | Novel use |
PCT/EP2000/005998 WO2001000232A2 (en) | 1999-06-29 | 2000-06-28 | Use of cpg as an adjuvant for hiv vaccine |
US1869502A | 2002-06-26 | 2002-06-26 | |
US11/748,229 US20080199494A1 (en) | 1999-06-29 | 2007-05-14 | Vaccine |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/005998 Continuation WO2001000232A2 (en) | 1999-06-29 | 2000-06-28 | Use of cpg as an adjuvant for hiv vaccine |
US1869502A Continuation | 1999-06-29 | 2002-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080199494A1 true US20080199494A1 (en) | 2008-08-21 |
Family
ID=26243523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/748,229 Abandoned US20080199494A1 (en) | 1999-06-29 | 2007-05-14 | Vaccine |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080199494A1 (en) |
EP (1) | EP1198249B1 (en) |
AT (1) | ATE306938T1 (en) |
AU (1) | AU5821000A (en) |
CA (1) | CA2376992A1 (en) |
DE (1) | DE60023300T2 (en) |
ES (1) | ES2250151T3 (en) |
WO (1) | WO2001000232A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
PT1733735T (en) | 1998-05-22 | 2017-06-16 | Ottawa Hospital Res Inst | Methods and products for inducing mucosal immunity |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
AU4343700A (en) | 1999-04-12 | 2000-11-14 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Oligodeoxynucleotide and its use to induce an immune response |
CA2380947C (en) | 1999-08-19 | 2011-11-01 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
AU2001227889A1 (en) | 2000-01-14 | 2001-07-24 | The United States of America, represented by The Secretary, Department of Health & Human Services | Oligodeoxynucleotide and its use to induce an immune response |
EP1279404A1 (en) | 2001-07-26 | 2003-01-29 | Istituto Superiore di Sanità | Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
WO2003020884A2 (en) | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
EP1450856B1 (en) | 2001-09-14 | 2009-11-11 | Cytos Biotechnology AG | Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
WO2003054161A2 (en) | 2001-12-20 | 2003-07-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
US8263091B2 (en) | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
AU2003283647B2 (en) | 2002-10-29 | 2010-04-15 | Coley Pharmaceutical Gmbh | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
US7758876B2 (en) | 2002-11-01 | 2010-07-20 | The United States Of America As Represented By The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
US7927580B2 (en) | 2004-03-16 | 2011-04-19 | Nanirx, Inc. | Tat-based immunomodulatory compositions and methods of their discovery and use |
JP4926060B2 (en) | 2004-08-17 | 2012-05-09 | アンスティテュ・グスターブ・ルシ | Mutated HIVNef to modulate immunity |
EP1973608A1 (en) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
DK2032592T3 (en) | 2006-06-12 | 2013-09-02 | Cytos Biotechnology Ag | PROCEDURES FOR PACKING OLIGONUCLEOTIDES FOR VIRUS LIKE PARTICLES OF RNA BACTERY PHAGES |
CN101668770B (en) * | 2007-01-15 | 2013-06-12 | 葛兰素史密丝克莱恩生物有限公司 | Vaccine |
AU2010230073B2 (en) | 2009-03-23 | 2016-05-26 | Pin Pharma, Inc. | Treatment of cancer with immunostimulatory HIV Tat derivative polypeptides |
WO2015051245A1 (en) | 2013-10-04 | 2015-04-09 | Pin Pharma, Inc. | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
GB2542425A (en) * | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
WO2021176434A1 (en) | 2020-03-01 | 2021-09-10 | Valneva Austria Gmbh | Cpg-adjuvanted sars-cov-2 virus vaccine |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5278302A (en) * | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5653985A (en) * | 1990-03-09 | 1997-08-05 | Chiron Corporation | Purified gp120 composition retaining natural conformation |
WO1999016884A1 (en) * | 1997-09-26 | 1999-04-08 | Smithkline Beecham Biologicals S.A. | Fusion proteins comprising hiv-1 tat and/or nef proteins |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0550485A1 (en) * | 1990-09-28 | 1993-07-14 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | DERIVATIVES OF gp160 AND VACCINES BASED ON gp160 OR A DERIVATIVE THEREOF, CONTAINING AN ADJUVANT |
ES2320315T5 (en) * | 1994-07-15 | 2012-12-05 | University Of Iowa Research Foundation | Immunostimulatory oligonucleotides |
US6214806B1 (en) * | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
NZ504894A (en) * | 1997-12-02 | 2002-12-20 | Powderject Vaccines Inc | Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique |
GB9727262D0 (en) * | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
NZ511113A (en) * | 1998-10-16 | 2002-09-27 | Smithkline Beecham Biolog S | Adjuvant systems containing an immunostimulant absorbed on to a metal salt particle and vaccines thereof |
PT1187629E (en) * | 1999-04-19 | 2005-02-28 | Glaxosmithkline Biolog Sa | ADJUVANT COMPOSITION THAT UNDERSTANDS SAPONIN AND AN IMMUNOSTIMULATOR OLIGONUCLEOTIDE |
BR0010323A (en) * | 1999-05-06 | 2002-01-08 | Immune Response Corp Inc | Immunogenic compositions, kit and method of making it for use in the immunization of a mammal |
-
2000
- 2000-06-28 DE DE60023300T patent/DE60023300T2/en not_active Expired - Lifetime
- 2000-06-28 ES ES00943919T patent/ES2250151T3/en not_active Expired - Lifetime
- 2000-06-28 WO PCT/EP2000/005998 patent/WO2001000232A2/en active IP Right Grant
- 2000-06-28 AT AT00943919T patent/ATE306938T1/en not_active IP Right Cessation
- 2000-06-28 CA CA002376992A patent/CA2376992A1/en not_active Abandoned
- 2000-06-28 AU AU58210/00A patent/AU5821000A/en not_active Abandoned
- 2000-06-28 EP EP00943919A patent/EP1198249B1/en not_active Expired - Lifetime
-
2007
- 2007-05-14 US US11/748,229 patent/US20080199494A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5278302A (en) * | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5653985A (en) * | 1990-03-09 | 1997-08-05 | Chiron Corporation | Purified gp120 composition retaining natural conformation |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
WO1999016884A1 (en) * | 1997-09-26 | 1999-04-08 | Smithkline Beecham Biologicals S.A. | Fusion proteins comprising hiv-1 tat and/or nef proteins |
Non-Patent Citations (1)
Title |
---|
Deml, L., et al., 1999, Immunostimulatory CpG motifs trigger a T-helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp160 envelope proteins, Clin. Chem. Lab. Med. 37(3):199-204. * |
Also Published As
Publication number | Publication date |
---|---|
DE60023300T2 (en) | 2006-07-06 |
WO2001000232A3 (en) | 2001-05-25 |
EP1198249A2 (en) | 2002-04-24 |
EP1198249B1 (en) | 2005-10-19 |
ES2250151T3 (en) | 2006-04-16 |
DE60023300D1 (en) | 2006-03-02 |
CA2376992A1 (en) | 2001-01-04 |
WO2001000232A2 (en) | 2001-01-04 |
AU5821000A (en) | 2001-01-31 |
ATE306938T1 (en) | 2005-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080199494A1 (en) | Vaccine | |
EP1326635B1 (en) | Pharmaceutical composition for immunisation against aids | |
AU2004254152B2 (en) | Quil a fraction with low toxicity and use thereof | |
AU749282B2 (en) | Immunostimulant emulsion | |
US8846080B2 (en) | Vaccine | |
KR101238795B1 (en) | Lyophilised antigen composition | |
JP7080513B2 (en) | Vaccine adjuvant containing lipopeptide-inserted liposome as an active ingredient and its use | |
JP5230780B2 (en) | Adjuvant mixed preparation | |
EP0855184A1 (en) | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination | |
CZ20022643A3 (en) | Pharmaceutical preparation | |
SK71397A3 (en) | Pharmaceutical compositions inducting cytotoxic t-lymphocyte response | |
CZ20001091A3 (en) | Fusion proteins containing proteins HIV-1TAT and/or NEF | |
CA2376926A1 (en) | Use of cpg as an adjuvant for malaria vaccine | |
AU2005222909A1 (en) | Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide | |
US20080131464A1 (en) | Vaccines | |
US7588764B2 (en) | Compositions comprising human immunodeficiency virus Tat adsorbed to the surface of anionic nanoparticles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GLAXOSMITHKLINE BIOLOGICALS SA, BELGIUM Free format text: CHANGE OF NAME;ASSIGNOR:SMTHKLINE BEECHAM BIOLOGICALS S.A.;REEL/FRAME:022536/0574 Effective date: 20010301 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |